TGTX
Price:
$22.03
Market Cap:
$3.41B
TG Therapeutics, Inc., a commercial stage biopharmaceutical company, focuses on the acquisition, development, and commercialization of novel treatments for B-cell malignancies and autoimmune diseases. Its therapeutic product candidates include Ublituximab, an investigational glycoengineered monoclonal antibody for the treatment of B-cell non-hodgkin lymphoma, chronic lymphocytic leukemia (CLL), and relapsing forms of multiple sclerosis; and Umbralisib, an oral inhibitor of PI3K-delta and CK1-epsilon for the treatment of CLL, marginal zone lymphoma, and follicular lymphoma. The company also develops Cosibelimab, a human monoclonal antibody of IgG1 subtype that binds to programmed death-ligand...[Read more]
Industry
Biotechnology
IPO Date
2010-05-03
Stock Exchange
NASDAQ
Ticker
TGTX
According to TG Therapeutics, Inc.’s latest financial reports and current stock price. The company's current PE Ratio is 32.40. This represents a change of 2.36% compared to the average of 1.32 of the last 4 quarters.
The mean historical PE Ratio of TG Therapeutics, Inc. over the last ten years is 12.26. The current 32.40 PE Ratio has changed 26.32% with respect to the historical average. Over the past ten years (40 quarters), TGTX's PE Ratio was at its highest in in the June 2024 quarter at 95.46. The PE Ratio was at its lowest in in the March 2024 quarter at -50.42.
Average
12.26
Median
-6.27
Minimum
-20.99
Maximum
191.33
Discovering the peaks and valleys of TG Therapeutics, Inc. PE Ratio, unveiling quarterly and yearly fluctuations to gain insights into the company’s financial performance and market dynamics, offering valuable data for investors and analysts alike.
Maximum Annual Increase = 283.72%
Maximum Annual PE Ratio = 191.33
Minimum Annual Increase = -2534.58%
Minimum Annual PE Ratio = -20.99
Year | PE Ratio | Change |
---|---|---|
2023 | 191.33 | -2534.58% |
2022 | -7.86 | 11.23% |
2021 | -7.07 | -66.33% |
2020 | -20.99 | 283.72% |
2019 | -5.47 | 206.65% |
2018 | -1.78 | -58.48% |
2017 | -4.30 | 47.42% |
2016 | -2.91 | -66.31% |
2015 | -8.65 | -10.58% |
2014 | -9.67 | 99.88% |
The current PE Ratio of TG Therapeutics, Inc. (TGTX) is less than than its 3-year, greater than its 5-year, and greater than its 10-year historical averages
3-year avg
58.80
5-year avg
29.99
10-year avg
12.26
TG Therapeutics, Inc.’s PE Ratio is greater than Madrigal Pharmaceuticals, Inc. (-10.23), greater than Intercept Pharmaceuticals, Inc. (-13.55), greater than Terns Pharmaceuticals, Inc. (-6.06), greater than Hepion Pharmaceuticals, Inc. (-0.15), greater than Exelixis, Inc. (20.78), greater than Viking Therapeutics, Inc. (-61.76), greater than BioXcel Therapeutics, Inc. (-0.20), greater than Akero Therapeutics, Inc. (-8.95), greater than Reata Pharmaceuticals, Inc. (-89.36), greater than X4 Pharmaceuticals, Inc. (7.41), greater than PDS Biotechnology Corporation (-2.64),
Company | PE Ratio | Market cap |
---|---|---|
-10.23 | $5.30B | |
-13.55 | $794.69M | |
-6.06 | $549.60M | |
-0.15 | $4.20M | |
20.78 | $7.17B | |
-61.76 | $6.00B | |
-0.20 | $22.26M | |
-8.95 | $1.83B | |
-89.36 | $6.57B | |
7.41 | $109.78M | |
-2.64 | $107.88M |
One of the best ways to find valuable stocks to invest in is to build a custom made screener in your Excel or Google Sheets spreadsheet. This allows you to compare thousands of companies like TG Therapeutics, Inc. using the financials and key metrics that matter to you in a single view.
The easiest way to set this up is to use the Wisesheets add-on and set your spreadsheet like this:
Covering all these metrics from financial, data, dividend data, key metrics and more you can get all the data you want for over 50+ exchanges worldwide.
Get your free trial here.
The easiest way to analyze a company like TG Therapeutics, Inc. or any others is to create a spreadsheet model that automatically retrieves all of the stock data you need.
Using Wisesheets you can set up a spreadsheet model like this with simple spreadsheet formulas. If you change the ticker you can get all of the data automatically updated for you.
Whether you need live data, historical price data, financials, dividend data, key metrics, analyst estimates, or anything else...Wisesheets has you covered.
What is the PE Ratio?
How can you use the PE Ratio?
What is TG Therapeutics, Inc.'s PE Ratio?
How is the PE Ratio calculated for TG Therapeutics, Inc. (TGTX)?
What is the highest PE Ratio for TG Therapeutics, Inc. (TGTX)?
What is the 3-year average PE Ratio for TG Therapeutics, Inc. (TGTX)?
What is the 5-year average PE Ratio for TG Therapeutics, Inc. (TGTX)?
How does the current PE Ratio for TG Therapeutics, Inc. (TGTX) compare to its historical average?